Cost-effectiveness of a centrifugal-flow pump for patients with advanced heart failure in Argentina.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
08
2021
accepted:
04
07
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
Centrifugal-flow pumps are novel treatment options for patients with advanced heart failure (HF). This study estimated the incremental cost-effectiveness ratio (ICER) of centrifugal-flow pumps for patients with advanced HF in Argentina. Two Markov models were developed to estimate the cost-effectiveness of a centrifugal-flow pump as destination therapy (DT) in patients with contraindication for heart transplantation, and as bridge-to-transplant (BTT), with a lifetime horizon using the third-party payer Social Security (SS) and Private Sector (PS) perspectives. Clinical, epidemiological, and quality-adjusted life years (QALY) parameters were retrieved from the literature. Direct medical costs were estimated through a micro-costing approach (exchange rate USD 1 = ARS 59.95). The centrifugal-flow pump as a DT increased the per patient QALYs by 3.5 and costs by ARS 8.1 million in both the SS and PS, with an ICER of ARS 2.3 million per QALY. Corresponding values for a centrifugal-flow pump as BTT were 0.74 QALYs and more than ARS 8 million, yielding ICERs of ARS 11 million per QALY (highly dependent on waiting times). For the 1, 3, and 5 GDP per QALY thresholds, the probability of a centrifugal-flow pump to be cost-effective for DT/BTT was around 2%/0%, 40%/0%, and 80%/1%, respectively. The centrifugal-flow pump prolongs life and improves the quality of life at significantly higher costs. As in Argentina there is no current explicit cost-effectiveness threshold, the final decision on reimbursement will depend on the willingness to pay in each subsector. Nevertheless, the centrifugal-flow pump as a DT was more cost-effective than as a BTT.
Sections du résumé
BACKGROUND
Centrifugal-flow pumps are novel treatment options for patients with advanced heart failure (HF). This study estimated the incremental cost-effectiveness ratio (ICER) of centrifugal-flow pumps for patients with advanced HF in Argentina.
METHODS
Two Markov models were developed to estimate the cost-effectiveness of a centrifugal-flow pump as destination therapy (DT) in patients with contraindication for heart transplantation, and as bridge-to-transplant (BTT), with a lifetime horizon using the third-party payer Social Security (SS) and Private Sector (PS) perspectives. Clinical, epidemiological, and quality-adjusted life years (QALY) parameters were retrieved from the literature. Direct medical costs were estimated through a micro-costing approach (exchange rate USD 1 = ARS 59.95).
RESULTS
The centrifugal-flow pump as a DT increased the per patient QALYs by 3.5 and costs by ARS 8.1 million in both the SS and PS, with an ICER of ARS 2.3 million per QALY. Corresponding values for a centrifugal-flow pump as BTT were 0.74 QALYs and more than ARS 8 million, yielding ICERs of ARS 11 million per QALY (highly dependent on waiting times). For the 1, 3, and 5 GDP per QALY thresholds, the probability of a centrifugal-flow pump to be cost-effective for DT/BTT was around 2%/0%, 40%/0%, and 80%/1%, respectively.
CONCLUSION
The centrifugal-flow pump prolongs life and improves the quality of life at significantly higher costs. As in Argentina there is no current explicit cost-effectiveness threshold, the final decision on reimbursement will depend on the willingness to pay in each subsector. Nevertheless, the centrifugal-flow pump as a DT was more cost-effective than as a BTT.
Identifiants
pubmed: 35913940
doi: 10.1371/journal.pone.0271519
pii: PONE-D-21-26630
pmc: PMC9342761
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271519Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Crit Care. 2018 Nov 13;22(1):293
pubmed: 30424796
Ann Thorac Surg. 2011 May;91(5):1330-3; discussion 1333-4
pubmed: 21439545
N Engl J Med. 2019 Apr 25;380(17):1618-1627
pubmed: 30883052
J Heart Lung Transplant. 2016 Jun;35(6):722-30
pubmed: 26987599
Appl Health Econ Health Policy. 2019 Feb;17(1):35-46
pubmed: 30345458
BMC Cardiovasc Disord. 2018 May 2;18(1):74
pubmed: 29716540
JACC Heart Fail. 2017 Feb;5(2):110-119
pubmed: 28017351
N Engl J Med. 2001 Nov 15;345(20):1435-43
pubmed: 11794191
Cost Eff Resour Alloc. 2021 Jul 9;19(1):40
pubmed: 34243782
Value Health. 2012 Sep-Oct;15(6):835-42
pubmed: 22999133
J Heart Lung Transplant. 2019 Oct;38(10):1042-1055
pubmed: 31548030
J Heart Lung Transplant. 2006 Nov;25(11):1336-43
pubmed: 17097498
Neuropharmacology. 2000 Mar 3;39(5):835-41
pubmed: 10699448
Nat Rev Cardiol. 2011 Jan;8(1):30-41
pubmed: 21060326
Value Health Reg Issues. 2017 Dec;14:73-80
pubmed: 29254545
Ann Thorac Surg. 2020 Mar;109(3):649-660
pubmed: 32115073
Stroke. 2001 Jun;32(6):1425-9
pubmed: 11387509
Ann Cardiothorac Surg. 2014 Sep;3(5):439-49
pubmed: 25452904
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
N Engl J Med. 2018 Apr 12;378(15):1386-1395
pubmed: 29526139
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
Circ Heart Fail. 2013 Jul;6(4):763-72
pubmed: 23674362
Value Health. 2018 Dec;21(12):1357-1364
pubmed: 30502778
Ann Thorac Surg. 1997 Dec;64(6):1764-9
pubmed: 9436569
PM R. 2017 Jan;9(1):40-45
pubmed: 27268564
ASAIO J. 2018 Jul/Aug;64(4):440-449
pubmed: 29084066
Open Heart. 2020 Jan 28;7(1):e001155
pubmed: 32076562
Heart. 2007 May;93(5):626-31
pubmed: 17435073
J Am Coll Cardiol. 2002 Oct 16;40(8):1414-21
pubmed: 12392830
Epidemiology. 2016 Jul;27(4):469-76
pubmed: 26928705
N Engl J Med. 2005 Jan 20;352(3):225-37
pubmed: 15659722
Int J Equity Health. 2020 Jul 31;19(1):67
pubmed: 32731876
Circ Heart Fail. 2014 May;7(3):470-8
pubmed: 24563450
JAMA Netw Open. 2021 Sep 1;4(9):e2122559
pubmed: 34519769
Value Health. 2008 Jul-Aug;11(4):733-41
pubmed: 18194399
Circ Heart Fail. 2013 May;6(3):606-19
pubmed: 23616602
N Engl J Med. 2004 May 20;350(21):2140-50
pubmed: 15152059
J Clin Oncol. 2000 Sep 15;18(18):3302-17
pubmed: 10986064
J Card Surg. 2020 Aug;35(8):1802-1810
pubmed: 32652710
J Heart Lung Transplant. 2015 Dec;34(12):1495-504
pubmed: 26520247
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
Value Health Reg Issues. 2019 Dec;20:142-148
pubmed: 31426017
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
Eur J Heart Fail. 2019 Nov;21(11):1306-1325
pubmed: 31523902
N Engl J Med. 2005 Oct 6;353(14):1471-80
pubmed: 16207849
Lancet. 1999 Jun 12;353(9169):2001-7
pubmed: 10376614
Int J Cardiol. 2014 Feb 15;171(3):338-45
pubmed: 24424339
Circulation. 2019 Jan 8;139(2):155-168
pubmed: 30586698
J Cardiopulm Rehabil Prev. 2017 Nov;37(6):390-396
pubmed: 28727672
Ann Thorac Surg. 2003 Jun;75(6 Suppl):S29-35
pubmed: 12820732
Acta Gastroenterol Latinoam. 2016 Mar;46(1):8-17
pubmed: 29470878
Health Syst Reform. 2018;4(3):203-213
pubmed: 30067439
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
BMJ. 2013 Mar 21;346:f1363
pubmed: 23518274
Heart Lung. 2018 May - Jun;47(3):177-183
pubmed: 29551363
Pharmacoeconomics. 2007;25(5):365-84
pubmed: 17488136
Rev Fac Cien Med Univ Nac Cordoba. 2018 Mar 19;75(1):3-11
pubmed: 30130479
J Heart Lung Transplant. 2013 Feb;32(2):157-87
pubmed: 23352391